Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.37 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308598 | 0.80 | GRM5 (0.52) | CSNK1DCSNK1EGRM5PTGDR2KDM1A | |
| SCHEMBL29308599 | 0.73 | GRM5 (0.44) | CSNK1DCSNK1EGRM5TRPC3TRPC7 | |
| SCHEMBL13254961 | 0.72 | MAPK14 (0.45) | CSNK1DCSNK1E | |
| SCHEMBL3108073 | 0.71 | GRM5 (0.43) | CSNK1DGRM5TRPC3TRPC7PTGDR2 | |
| SCHEMBL29308604 | 0.71 | TRPC3 (0.39) | CSNK1DCSNK1EGRM5TRPC3TRPC7 | |
| SCHEMBL24348526 | 0.68 | GRM5 (0.43) | GRM5PTGDR2KDM1AF2F12 | |
| SCHEMBL2857891 | 0.68 | SMN1; SMN2 (0.55) | HTT | |
| SCHEMBL19998108 | 0.66 | THRB (0.45) | CSNK1DCSNK1EKCNK3 | |
| SCHEMBL23243031 | 0.65 | SMN1; SMN2 (0.73) | HTT | |
| SCHEMBL26969090 | 0.65 | MEN1 (0.45) | GRM5PTGDR2F2F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | CSNK1D 1243/4885CSNK1E 1569/4885GRM5 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.